Evaluating Ifosfamide/Mesna for Advanced Prostate Cancer
Official title: Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Run by Yonsei University · NCT06236789 · Data updated 2026-11-12
This study is testing whether a combination of ifosfamide and mesna can help people with advanced prostate cancer who haven't had success with other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | Men only |
| Enrollment | 60 (estimated) |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | November 2016 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | February 1, 2024 |
| Trial ID | NCT06236789 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult males aged 19 and older with histologically confirmed castration-resistant prostate cancer who have previously been treated with docetaxel.
✕Probably not a fit
Patients with hormone-sensitive prostate cancer or those who have previously been treated with ifosfamide will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the efficacy and safety of ifosfamide combined with mesna in patients suffering from metastatic castration-resistant prostate cancer. It involves a retrospective analysis of treatment outcomes for patients who have previously undergone standard therapies and are now receiving ifosfamide/mesna as salvage therapy. The study will collect demographic data, disease status, treatment details, and survival information to analyze correlations between clinical indicators and survival rates.
Why it matters
Potential benefit: If successful, this study could provide a new salvage therapy option for patients with metastatic castration-resistant prostate cancer who have exhausted standard treatment options.
How similar studies have gone: While there is limited research specifically on ifosfamide/mesna for this condition, other studies have explored various salvage therapies for metastatic castration-resistant prostate cancer, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 19 years and older adult male 2. Patients with histologically confirmed prostate cancer 3. Castration-resistant prostate cancer 4. ECOG 2 or less 5. Patients with previous docetaxel exposure 6. Patients with available PSA level 7. Patients with evaluable disease based on RECIST 1.1 Exclusion Criteria: 1. Patients with other primary cancers diagnosed within 3 years other than prostate cancer 2. Patients with a history of organ transplantation 3. Hormone sensitive prostate cancer 4. ECOG 3 or higher 5. Patients without previous docetaxel exposure 6. Patients previously exposed to ifosfamide 7. Patients without available PSA level 8. Patients without evaluable disease based on RECIST 1.1
Where it's running
-
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Sang Joon Shin — Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- Study coordinator: Sang Joon Shin
- Email: inspector@yuhs.ac
- Phone: 82-2-2228-8130
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using AI to help find prostate cancer on MRI
This study tests whether an AI software can help doctors find suspicious lesions on prostate MRI in men aged 55–80 who are having a pre-biopsy MRI and planned prostate biopsy.
-
Understanding how obesity-related factors influence prostate cancer progression
This study looks at how being overweight or obese affects prostate cancer by checking certain enzymes and immune cells in tumor samples from patients with different body weights.
-
Using augmented reality to improve prostate cancer surgery outcomes
This study is testing whether using augmented reality during prostate cancer surgery can lead to better outcomes and help preserve erectile function compared to standard surgery methods.
-
Understanding factors affecting prostate cancer progression
This study is trying to find out what factors affect how prostate cancer grows in different people to help improve treatment and prevention for those at higher risk.
-
Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations
This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.
-
Evaluating genetic risk and screening for prostate cancer
This study is testing if prostate MRIs can help men at high genetic risk for prostate cancer find aggressive forms of the disease earlier.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.